Final Conference Program - aatod

More documents

Recommendations

Info

Exhibit and Poster Sessions The National Conference serves as a central gathering point for the opioid treatment community and offers significant opportunities for exhibiting companies and attendees to interact with other professionals who are devoted to the treatment of opioid dependence throughout the nation and abroad. The registrants will consist of the decision makers in this field who spend over $1 billion annually treating more than 260,000 patients in opioid treatment programs. In order to provide exhibitors with steady exposure to conference attendees, all continental breakfasts, refreshment breaks and poster sessions will be held exclusively in the exhibit area. An Exhibitors Networking Refreshment Event will be held Monday, October 25th from 3:00–4:00 p.m. to encourage contact and dialogue between opioid treatment professionals and the exhibiting companies. Exhibit Hours Monday, October 25: 7:30 a.m.–9:30 a.m.; 11:30 a.m.–4:30 p.m. Tuesday, October 26: 7:30 a.m.–1:30 p.m. Posters are in place at all times when the exhibit hall is open. Authors will present their topic on Tuesday from 7:30 a.m.– 8:45 a.m. 1A Results from the First Mortality Data Collection Effort in Opioid Treatment Programs Jane Maxwell, PhD, Gulf Coast Addiction Technology Center 1B Proposed 2010 Mortality Data Collection Form for Opioid Treatment Programs Jane Maxwell, PhD, Gulf Coast Addiction Technology Center 2 Successful Hepatitis A & B Vaccination Project in an Opiate Treatment Program Michelle Kletter, BAART 3 Integration of Methadone Maintained Pregnant Women into Residential Care Medication Safety Issues Alicia Kletter, NP, BAART Programs FACET 4 Social Networking Media and OTPs— Opportunities to Improve Communication and Treatment Outcome Trusandra Taylor, MD, JEVS Human Services 5 Medication Assisted Recovery with Vivitrol for Poly-Substance Dependence—Case Series from 2006–2010 Punyamurtula Kishore, MD, Fitchburg State College 6 Massachusetts Home Detoxification Model — An Integration of Public Health and Primary Care Punyamurtula Kishore, MD, Preventive Medicine Associates 7 Implementation of an Electronic Information System Lawrence Brown, Jr., MD, Addiction Research and Treatment Corporation 8 30-HIV/AIDS-Related Health Services in Substance Abuse Treatment Programs Lawrence Brown, Jr., MD, Addiction Research and Treatment Corporation 9 Partnerships—A Vocational Perspective Michele Buoninfante, BMIC, Beth Israel Medical Center – MMTP 10 Transformation through Partnerships—Evolution of Methadone Maintenance in the 21st Century Michele Buoninfante, BMIC, Beth Israel Medical Center – MMTP 11 An Examination of How Abstinence/Moralitybased Narratives of Addiction Effect the Treatment Decisions of Opiate Addicts David Frank, BA, DePaul University 12 Improving Access to Buprenorphine Services Robert Freeman, BS, APT Foundation, Inc. 13 Comparison of Psychosocial Treatments added to Pharmacotherapy with Buprenorphine Albert Hasson, MSW, UCLA Integrated Substance Abuse Programs 14 Mobile Medication Units and Office Based Services for Opioid Addicted Clients Jude Iheoma, PhD, State of New Jersey, Division of Addiction Services 15 Differences in Retention by Buprenorphine Treatment Site Albert Hasson, MSW, UCLA Integrated Substance Abuse Programs NEW for 2010 Trivia! Please visit the Exhibit Hall and answer questions to enter a drawing for prizes from AATOD at the Closing Plenary. See insert in your registration materials for additional information. 10 AATOD National Conference | Building Partnerships: Advancing Treatment & Recovery
Southwest Hall 16 Sex and Drug Using Behavior Among HIV + African Americans and Hispanics in an MMTP James Mitchell, Addiction Research and Treatment Corporation 17 Safe Methadone Induction/Stabilization—A Best Practice Approach to Improve Patient Awareness and Knowledge Judith Prophete, MD, JEVS Human Services 18 SMS (Social and Health Service)— Make the Link Inside Outside! Andre Jean Remy, MD, Centre Hospitalier 19 Needle Exchange in Prison —Two-Thirds of the Jailhouse Medical Units Are Ready in France! Preliminary Results of the National Harm Reduction Survey Andre Jean Remy, MD, Centre Hospitalier 20 Transformation Through Partnerships —Evolution of Methadone Maintenance in the 21st Century Bonnie Robbins, PhD, Beth Israel Medical Center 21 Opioid Relapse Rates Among a Sample of New Buprenorphine–Medication Assisted Treatment Patients—Relationship with Medication Compliance at One Year Charles Ruetsch, PhD, Health Analytics, LLC 22 Refusal of Ancillary Support Services Early in Opioid Dependence in Opioid Dependence Treatment Predicts Six Month Buprenorphine-Medication Assisted Treatment Compliance Charles Ruetsch, PhD, Health Analytics, LLC 23 Sublingual Buprenorphine Treatment of Opioid Dependence in American Indians Anthony Dekker, DO, Indian Health Service 24 Comparison of a Prescription Based Outpatient Buprenorphine Program with a Dispensed Buprenorphine Program in a Community Setting David Parcher, MA, Kent Sussex Counseling Services 25 Office-Based Pharmacy-Based Program— A Novel Medical Maintenance Model for OAT in New York City Ann Beeder, MD, Weill Cornell Medical College 26 Opiate Addiction Treatment Patients and Chronic Pain—How Data Can Help Improve Practice Erin Stevenson, MSW, University of Kentucky 27 Methadone Maintenance Outcomes—Quality of Life and Patient Self Esteem Examined in Relation to Anecdotal Evidence of Patients Desire to Discontinue Treatment Joseph Stanley, BS, Denver Health Medical Center–OBHS 28 Prescription Opioid Abuse and other Factors Associated with First Time Admission into an Opioid Treatment Program Andrew Rosenblum, PhD, NDRI 29 Disaster Planning and Substance Abuse Stigma with Respect to Methadone Maintenance Treatment Deborah Podus, PhD, UCLA Integrated Substance Abuse Programs 30 Methadone Maintenance Treatment Patients Characterized with High Rate of ADHD and OCD— And Low Rate of Pathological Gambling Einat Peles, PhD, Adelson Clinic for Drug Abuse Treatment and Research 31 Buprenorphine at Syringe Exchange Herman Joseph, PhD, NDRI Consultant 32 Program Development and Patient Characteristics Associated with Overdose Prevention Education and Training Within Opioid Dependence Treatment Programs Lynn Madden, MPA, The APT Foundation and Yale University 33 Maternal and Neonatal Methadone Issues— Who are We Treating Maureen Elston, ARNP, Spokane Regional Health District– Methadone Program 34 Opioid Addiction Treatment Modalities In Ukraine Natalya Vlasova, MA, NGO STEPS Vinnytsia Branch Ukraine–AATOD Posters are not approved for Continuing Education Credits. Exhibitors Networking Refreshment Break Monday, October 25, 2010 3:00 p.m.–4:00 p.m. Southwest Hall Sponsored in part by: Atlantic Diagnostic Laboratories, Kols Containers Inc/OBerk New England, Tower Systems, and VistaPharm. October 23–27, 2010 | Hilton Chicago, Chicago, Illinois 11
Page 1 and 2: NATIONAL CONFERENCE Building Partne
Page 3 and 4: LETTER FROM THE CONFERENCE CHAIR De
Page 5 and 6: Pre-Conference Sessions Saturday, O
Page 7 and 8: MODULE DESCRIPTIONS Module One: Int
Page 9 and 10: The session also provides nurses wi
Page 11: disorders, medical care and vocatio
Page 15 and 16: presented will include neonatal and
Page 17 and 18: This workshop will preview and disc
Page 19 and 20: will discuss the collaborative proc
Page 21 and 22: with serum levels, and collaborativ
Page 23 and 24: Conference Sessions Wednesday, Octo
Page 25 and 26: F5 Using Patient Chart Audits to Im
Page 27 and 28: ecap and a valuable training tool t
Page 29 and 30: Sweet Home Chicago “C’mon, Oh b
Page 31 and 32: Alkermes, Inc. is a fully integrate
Page 33 and 34: medical, social, and public health
Page 35 and 36: Continuing Education SAMHSA is a pu

Final Conference Program - aatod

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?